Lisinopril dihydrate

SKU: orb1310366

Description

Lisinopril dihydrate (MK-521) is a long-acting, orally active angiotensin-converting enzyme (ACE) inhibitor used as an antihypertensive agent. It is widely employed in cardiovascular research, including in vitro enzyme inhibition assays and in vivo models of hypertension and heart failure.

Research Area

Immunology & Inflammation, Metabolism Research

Key Properties

• CAS Number: 83915-83-7
• MW: 441.52
• Purity: 99.87% (May vary between batches)
• Formula: C₂₁H₃₅N₃O₇
• SMILES: O.NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O
• Target: Angiotensin-converting Enzyme (ACE),MRP,RAAS
• Solubility: H2O:10 mM;DMSO:Insoluble

Bioactivity

• In Vivo:
  Lisinopril treated SHR rats has significantly raised total cholesterol levels compared to untreated spontaneously hypertensive rats (SHR) rats (+27%), but not compared to lisinopril treated Wistar Kyoto rats (WKY) rats. Lisinopril is a long-acting angiotensin-converting enzyme inhibitor which blocks the renin-angiotensin system (RAS) and reduces systemic blood pressure in rats. Lisinopril reduces the hydroxyproline level and inhibits accumulation of collagens in the pulmonary tissue of the treatment group (paraquat + lisinopril) and per-treatment group (lisinopril + paraquat) in rats. Lisinopril results in preserved ultrafiltration volume (UF), glucose reabsorption (D 1 /D 0 glucose) and peritoneal thickness in rats. Lisinopril (0.2 mg/kg twice a day for 10 days) protects the cell membrane integrity and lessens free radical-induced oxidant stress in guinea pig hearts.
• In Vitro:
  Lisinopril significantly reduces left ventricular (LV) end-diastolic pressure (EDP), pulmonary capillary wedge pressure (PCWP) and end-diastolic stress, addition of atenolol to Lisinopril further reduces EDP and PCWP. Lisinopril is a structural homologue of enalaprilat, differing only in the second amino acid side chain. Lisinopril inhibits Angiotensin-converting enzyme (ACE) in vitro, as well as after parenteral and oral administration to humans; its oral bioavailability is only 25-29%, but it has a longer duration of action than enalapril.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Renacor, MRP1, MK 521, MK521, MK-521, MK-521 (dihydrate), MK-521 dihydrate, ACE

Compound Identifiers

PubChem CID

5362118